S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
NASDAQ:NERV

Minerva Neurosciences - NERV Stock Forecast, Price & News

$3.13
+0.03 (+0.97%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.00
$3.20
50-Day Range
$2.53
$4.95
52-Week Range
$2.51
$17.04
Volume
125,214 shs
Average Volume
289,503 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,178.0% Upside
$40.00 Price Target
Short Interest
Healthy
0.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
1.01mentions of Minerva Neurosciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.86) to ($5.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

160th out of 1,124 stocks

Pharmaceutical Preparations Industry

67th out of 555 stocks

NERV stock logo

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Minerva Neurosciences in a research note on Wednesday. They set a "sell" rating on the stock.

Minerva Neurosciences Trading Up 1.0 %

Shares of NERV opened at $3.13 on Wednesday. Minerva Neurosciences has a twelve month low of $2.51 and a twelve month high of $17.04. The company has a market cap of $16.71 million, a P/E ratio of -0.34 and a beta of 0.92. The company's fifty day simple moving average is $3.20 and its 200-day simple moving average is $4.48.

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Stock News Headlines

Minerva Neurosciences, Inc. (NERV)
See More Headlines
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Company Calendar

Last Earnings
11/08/2021
Today
8/16/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NERV
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+1,178.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-49,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$41.18 million
Book Value
$1.49 per share

Miscellaneous

Free Float
4,488,000
Market Cap
$16.71 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 61)
    Exec. Chairman & CEO
    Comp: $1.19M
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 61)
    FCMA, M.B.A., MBA, Pres
    Comp: $880.44k
  • Mr. Frederick W. Ahlholm CPA (Age 56)
    CPA, Sr. VP, CFO & Sec.
    Comp: $610.68k
  • Dr. Michael Davidson M.D. (Age 72)
    Chief Medical Officer
    Comp: $657.47k
  • Mr. Joseph Reilly (Age 47)
    Sr. VP & COO
  • Mr. William B. Boni (Age 70)
    VP of Investor Relations & Corp. Communications
  • Dr. Ramana Kuchibhatla Ph.D.
    Sr. VP and Head of R&D













NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NERV shares.
View NERV analyst ratings
or view top-rated stocks.

What is Minerva Neurosciences' stock price forecast for 2022?

1 brokerages have issued twelve-month target prices for Minerva Neurosciences' stock. Their NERV share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,178.0% from the stock's current price.
View analysts price targets for NERV
or view top-rated stocks among Wall Street analysts.

How have NERV shares performed in 2022?

Minerva Neurosciences' stock was trading at $6.4080 at the beginning of 2022. Since then, NERV stock has decreased by 51.2% and is now trading at $3.13.
View the best growth stocks for 2022 here
.

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NERV earnings forecast
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($1.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.76). During the same period last year, the company earned ($1.52) EPS.

When did Minerva Neurosciences' stock split?

Shares of Minerva Neurosciences reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.49%), Group One Trading L.P. (0.00%), FMR LLC (0.94%), Sei Investments Co. (0.71%), Renaissance Technologies LLC (0.67%) and State Street Corp (0.26%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends
.

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.13.

How much money does Minerva Neurosciences make?

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $16.71 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($9.23) on an earnings per share basis.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.